Investors weighing exposure to the life sciences and genomics sectors frequently encounter two distinct profiles: RVTY (Revvity, Inc.), a diversified provider of diagnostics and research tools, and TWST (Twist Bioscience Corporation), a synthetic biology company focused on DNA synthesis. This stock comparison examines how these two companies differ in business model, profitability, momentum, and market positioning. It is most relevant for traders and investors deciding between a steady, cash-generating healthcare technology franchise and a faster-growing but unprofitable growth story tied to AI-driven drug discovery. Understanding their relative performance and risk profiles can help clarify which better fits a given portfolio objective. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Revvity, formerly PerkinElmer, provides health sciences solutions spanning instruments, reagents, software, and diagnostic platforms used in research, newborn screening, and infectious disease testing. In recent weeks, the company reported quarterly revenue of approximately $729 million, up 10.3% year over year, with pro forma organic growth of about 7%. Management credited improving demand from pharmaceutical and biotechnology customers, broad-based diagnostics strength, and incremental demand related to artificial intelligence (AI) workflows. Revvity also raised its full-year revenue and adjusted earnings guidance, and continued advancing the divestiture of its China Immunodiagnostics business. The stock has delivered strong relative performance, with a year-to-date return well above the S&P 500, reflecting solid momentum and improving end-market conditions across its two core segments.
Twist Bioscience writes DNA on silicon using a proprietary semiconductor-based platform, enabling customers to synthesize millions of unique DNA sequences in parallel. Its two segments — next-generation sequencing (NGS) applications and DNA synthesis and protein solutions (DSPS) — have driven accelerating growth. In its most recent fiscal quarter, revenue rose 28% to about $126.6 million, marking a 15th consecutive quarter of sequential growth, and the company achieved its first positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) quarter. AI drug discovery revenue surged roughly 175% year over year to about $59 million for the fiscal year. However, the company remains unprofitable on a GAAP basis, and shares pulled back sharply after fiscal 2027 guidance implied a deceleration in base-business growth, underscoring the stock's sensitivity to expectations. From what I see, this highlights the execution risks that come with rapid expansion.
The two companies differ sharply in business model and financial profile. Revvity is a diversified, profitable operator with positive adjusted earnings, strong free cash flow conversion, and a market capitalization near $17 billion. Twist Bioscience is a smaller, faster-growing company with a market capitalization under $10 billion that is still generating GAAP net losses. Growth drivers also diverge: Revvity benefits from recovering pharma and biotech demand and early AI-related instrument and reagent demand, while Twist is leveraged more directly to the expansion of AI-enabled drug discovery and personalized medicine. On momentum, both have posted impressive 2026 gains, but Twist's shares are considerably more volatile, reacting sharply to guidance nuance, while Revvity's price action has been steadier. From a risk standpoint, Twist carries greater valuation and execution risk tied to unproven profitability, whereas Revvity's principal risks include China exposure and moderating near-term growth.
Based on observable factors, Tickeron's AI would likely favor RVTY over TWST in the current environment. Revvity combines established profitability, strong free cash flow, broad-based organic growth, and a track record of consistent guidance increases — characteristics associated with trend consistency and stability. Twist Bioscience offers superior top-line growth and an attractive AI drug discovery narrative, but its continued GAAP losses, higher volatility, and sensitivity to guidance expectations introduce greater uncertainty. While both stocks hold valid long-term investment theses, the balance of stability, catalysts, and relative positioning currently tilts the AI's assessment toward Revvity.
In my analysis of these names, I turned to Tickeron’s AI Trend Prediction Engine to evaluate forward momentum and compare trend signals across the sector. This helped confirm the steadier profile for one name over the other based on historical patterns and current data inputs. It offers a practical way to layer quantitative insights onto fundamental research without replacing individual judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 31 of the 39 cases the stock fell afterwards. This puts the odds of success at 79%.
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 17 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 34 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
RVTY moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on RVTY as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 117 of 189 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.394) is normal, around the industry mean (67.298). P/E Ratio (74.572) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of analytical instruments
Industry MedicalSpecialties